Jia, Siyue
Zhang, Jinlong
Wang, Xue
Zhang, Zhe
Wang, Busen
Zhang, Jun
Jiang, Hudachuan
Guo, Ge
Wang, Ying
Wan, Jingxuan
Wang, Wenjuan
Hou, Lihua
Zhu, Fengcai
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18–60 Years: a Single-Center, Open-Label Trial
https://doi.org/10.1007/s40121-023-00892-0
Funding for this research was provided by:
National Key R&D Program of China (2020YFC10841400)
National Science and Technology Major Project (2016ZX10004001, 2018ZX09201005)
Article History
Received: 7 September 2023
Accepted: 6 November 2023
First Online: 1 December 2023
Declarations
:
: Xue Wang, Ge Guo, Ying Wang, and Jingxuan Wan are employees of CanSino Biologics. Siyue Jia, Jinlong Zhang, Zhe Zhang, Busen Wang, Jun Zhang, Hudachuan Jiang, Wenjuan Wang, Lihua Hou and Fengcai Zhu have no competiting interests.
: The trial protocol and informed consent form were reviewed and approved by the institutional review board of the Jiangsu Provincial Center of Disease Control and Prevention (JSJK2020-A055-01). This trial was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice.